SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing a sharp sell-off following the announcement that Marvell cancelled purchase orders due to an alleged breach of confidentiality triggered by recent public comments from the company's CFO. While the community remains deeply divided between those calling the stock a fundamental failure and others who view the dip as a tactical buying opportunity, the primary concern is the potential erosion of trust with future hyperscale partners.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors weigh strong AI and automotive growth potential against near-term headwinds like supply chain constraints and cautious analyst sentiment. The stock is a primary focus for the community, which remains divided on whether the current price represents a buying opportunity or a deeper structural decline.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as they await topline Phase 3 data from the HAELO trial, which the community sees as a potential validation for their in vivo CRISPR platform. Traders are actively debating the high short interest and the stock's susceptibility to a squeeze, with many weighing the clinical promise of a functional HAE cure against the broader volatility affecting the biotech sector.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is gaining significant momentum as investors digest a new share buyback program and the upcoming elimination of pattern day trading (PDT) restrictions. The community is actively debating the stock's valuation relative to its growth potential, with many discussing potential short squeeze setups and comparing its market positioning to peers like Robinhood.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is experiencing significant bullish momentum driven by heavy short interest and mounting anticipation for its acquisition of Northern Data, which effectively expands its cloud and GPU infrastructure. The community is actively discussing a potential short squeeze, citing record-high short interest and strong backing from strategic partner Tether as catalysts for a potential rally.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant investor interest as it approaches a high-profile oral presentation of pancreatic cancer data at Digestive Disease Week, which the community views as a critical catalyst for the stock. Traders are actively accumulating shares, citing strong scientific momentum and the company's progress in expanding global clinical trials.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing significant market movement driven by speculative interest in its shift toward custom AI chip design and high-performance server CPUs. Community discussions are split between euphoria over its long-term potential as an AI infrastructure backbone and intense debate regarding its valuation, with many traders actively debating the merits of aggressive shorting versus holding for a potential parabolic breakout.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares is experiencing massive volatility and bullish momentum driven by a strong semiconductor sector rally, fueled by earnings optimism and ongoing AI infrastructure spending. Investors are actively debating whether the current parabolic price action signifies a sustainable super-cycle or a speculative bubble, leading to intense sentiment clashes between bullish 'diamond hands' and traders betting on a sharp mean reversion.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently seeing significant investor attention driven by positive Phase 3 acne data and the potential for its FASN inhibitor denifanstat as a cornerstone MASH treatment. The community is actively debating the company's valuation, the strategic shift toward combination therapies, and the high probability of a future buyout given the surge in M&A activity within the metabolic disease sector.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is generating significant investor buzz as it makes its market debut, with the community highlighting its strategic backing from major players like Amazon and Dow to address the surging energy demands of AI data centers. Traders are actively debating the company's valuation and long-term potential compared to other modular nuclear reactor peers, fueled by high initial demand and its positioning as a key player in the clean energy infrastructure space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Alpha Tau’s IMPACT study is a multi-center trial across the U.S., Canada, and Israel, focusing on patients with recently diagnosed, inoperable pancreatic adenocarcinoma.</li><li>The main goal of the study is to evaluate safety, feasibility, and tolerability, track tumor response, disease progression, and survival outcomes</li><li>The biotech firm also marked the debut of its Alpha DaRT therapy for pancreatic cancer in Europe.</li></ul>Shares of Alpha Tau Medical (DRTS) drew strong retail attention on Friday, rising nearly 4% in pre-market trading after the company announced key progress in its pancreatic cancer program, including regulatory approval to expand its ongoing trial by enrolling an additional 10 patients.On Thursday, the U.S. Food and Drug Administration (FDA) cleared an Investigational Device Exemption (IDE) supplement to expand its pancreatic cancer study, known as the IMPACT trial, which is testing its Alpha DaRT therapy alongside chemotherapy.The update allows the company to enroll 10 additional patients receiving the chemotherapy combination Gemcitabine and Abraxane, split evenly between locally advanced and metastatic pancreatic cancer cases. This expansion takes the total enrollment to 40 patients.The IMPACT study is a multi-center trial across the U.S., Canada, and Israel, focusing on patients with recently diagnosed, inoperable pancreatic adenocarcinoma. The main goal of the study is to evaluate safety, feasibility, and tolerability, while also tracking tumor response, disease progression, survival outcomes, and patient-reported pain relief.<h2 class="st-heading-2">Retail Bullish On Trial Expansion</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/DRTS">DRTS</a> on Stocktwits turned ‘bullish’ from ‘neutral,’ a day earlier, amid ‘high’ message volumes. Chatter on the platform was up by 200% over the past 24 hours.One user said the trial expansion wouldn’t have taken place if the “safety profile wasn’t looking solid.”<stembedurl>https://stocktwits.com/mattstk2000/message/651253093</stembedurl>Another user was bullish on the company’s prospects for treating pancreatic cancer.<stembedurl>https://stocktwits.com/Pristine_Hurry/message/651252964</stembedurl><h2 class="st-heading-2">Treats First Patient In Europe</h2>Alpha Tau Medical also said it treated the first patient in its ACAPELLA trial, marking the debut of its Alpha DaRT therapy for pancreatic cancer in Europe. The study is testing Alpha DaRT alongside Capecitabine in patients with inoperable, locally advanced disease who have already completed standard chemotherapy.Management said the trial targets a major care gap, as there is currently no standard follow-up treatment for such patients. Pancreatic cancer remains highly lethal, with about 30% of Europe’s 140,000 annual cases diagnosed at this stage.“Over forty thousand Europeans each year are diagnosed with inoperable locally advanced pancreatic cancer, and even if there are some patients who have managed to complete first-line chemotherapy, there remains no established next step, no standard treatment path, and an inevitable progression for the great majority. That is the great unmet need ACAPELLA was designed to address,” CEO Uzi Sofer said.DRTS shares have surged more than 57% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-ogn-stock-rising-in-pre-market-today/cZBWU3fReTp">Why Is OGN Stock Rising In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

DRTS Stock Pops Pre-Market: Retail Hype Soars On Cancer Trial Expansion

The company announced key progress in its pancreatic cancer program, including regulatory approval to expand its ongoing trial by enrolling an additional 10 patients.

DRTS Is Back On Retail Radar: These Two Catalysts Are Driving The Rally

Equity

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives Consensus Rating of "Hold" from Brokerages

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five research firms that are presently covering the stock, Marketbeat...

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 771,223...

Apella Capital LLC Buys New Position in Alpha Tau Medical Ltd. $DRTS

Apella Capital LLC bought a new stake in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange...

Alpha Tau Medical (NASDAQ:DRTS) Shares Up 5.2%  - Here's What Happened

Alpha Tau Medical (NASDAQ:DRTS) Shares Up 5.2% - Still a Buy...

Daytona Street Capital LLC Invests $749,000 in Alpha Tau Medical Ltd. $DRTS

Daytona Street Capital LLC purchased a new position in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F...

<ul class="summary-bullets"><li>Alpha Tau’s IMPACT trial is expected to enroll up to 30 patients across the U.S., Canada, and Israel, focusing on patients with newly diagnosed, inoperable pancreatic adenocarcinoma.</li><li>The ReSTART study is to evaluate Alpha DaRT in patients with recurrent cutaneous squamous cell carcinoma, a common form of skin cancer.</li><li>Patient enrollment for both trials is expected to be completed by the end of the first quarter of 2026.</li></ul>Alpha Tau Medical (DRTS) drew strong retail attention on Monday as the oncology therapeutics firm approaches a key catalyst, with markets awaiting crucial patient enrolment data in pancreatic cancer and cutaneous squamous cell carcinoma (cSCC) trials.<a href="https://stocktwits.com/symbol/DRTS">DRTS shares</a> were down 4% in pre-market trading at the time of writing.<h2 class="st-heading-2">IMPACT Study For Pancreatic Cancer</h2>Alpha Tau’s IMPACT trial is expected to enroll up to 30 patients across the U.S., Canada, and Israel, focusing on those with newly diagnosed, inoperable pancreatic adenocarcinoma. Patient enrollment is expected to be completed by the end of the first quarter of 2026.Participants will continue standard chemotherapy while receiving the company’s Alpha DaRT, a targeted radiation therapy delivered directly into tumors using ultrasound-guided endoscopy.The study aims to evaluate the safety, feasibility, and effectiveness of the treatment, while also tracking tumor response and survival outcomes. Researchers will additionally assess whether some patients with locally advanced disease become eligible for surgery after treatment, a key potential benefit of the therapy, the company said.<h2 class="st-heading-2">ReSTART Trial Targets Skin Cancer Opportunity</h2>Alpha Tau is currently running its multi-center ReSTART study to evaluate Alpha DaRT in patients with recurrent cutaneous squamous cell carcinoma (cSCC), a common form of skin cancer. Patient enrollment is expected to be completed in the first quarter of 2026.The trial supports the use of Alpha DaRT, particularly for patients who are not eligible for surgery or standard radiation.The company has already secured Breakthrough Device Designation from the U.S. Food and Drug Administration for this indication, as well as for recurrent glioblastoma multiforme, a type of brain tumor, and oral cavity cancers.This designation reflects the regulator’s view that the therapy could offer significant advantages over existing treatments and allows for an accelerated review and development pathway. It is also part of the FDA’s Total Product Life Cycle Advisory Program.<h2 class="st-heading-2">DRTS Stock: Retail Sentiment Signals High Expectations&nbsp;</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, accompanied by ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/DRTS_jpg_933216b5d9.webp" alt="DRTS.jpg">Chatter was largely bullish, with one user stating that the company’s current market value could look very low in hindsight if there are further positive updates from the ReSTART trial.<stembedurl>https://stocktwits.com/Joshsim123/message/648904774</stembedurl>Another user said the stock’s current value feels like a “massive mispricing.”<stembedurl>https://stocktwits.com/Jessypenny/message/648902299</stembedurl>Year-to-date, the stock has gained nearly 38%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/soc-stock-gains-california-pipeline-restart-sales/cZERVWqRIZt">Sable Offshore Begins Oil Sales From Highly Scrutinized California Pipeline – SOC Stock Gains 3% Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

DRTS Stock Is Back On Retail Radar Ahead Of High-Stakes Cancer Trial Updates

The market is awaiting the company’s patient enrolment data from pancreatic cancer and cutaneous squamous cell carcinoma trials, a key factor in advancing the studies.

Why Alpha Tau Is Back On Traders’ Radar? 

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Given Average Recommendation of "Hold" by Brokerages

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) has received a consensus rating of "Hold" from the five brokerages that are covering the firm, Marketbeat Ratings reports. One equities research...

Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up   - Here's Why

Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up - Here's What Happened...

Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased

Alpha Tau Medical (NASDAQ:DRTS) provided investors with a series of clinical, regulatory and financial updates, highlighting what company leadership described as real and meaningful activity over the...

Earnings

Fed / Macro data

Headlines / Geopolitics

Other (drop a comment)

What will be the main driver of the market this week?

Stocktwits

Stocktwits Polls

Traders are intensely focused on the upcoming May 2nd Digestive Disease Week oral presentation as the primary short-term spark for a potential breakout.

Bullish sentiment is building around a significant price climb as investors speculate that the stock will move beyond $10 in the near future.

Recent clinical milestones, including EU trial expansion and FDA approvals, have fueled optimism that the company is cracking the high-value pancreatic cancer market.

Long-term investors argue the current price does not reflect the clinical data momentum or the company's strong technological patent portfolio.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.12	--	--	N/A
Q4 '25	-$0.12	--	--	N/A
Q3 '25	-$0.12	--	--	N/A
Q2 '25	-$0.11	-$0.13	-17.33%	MISSED
Q1 '25	-$0.13	-$0.12	5.90%	BEAT

DRTS
ALPHA TAU MEDICAL LTD

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest DRTS News

DRTSALPHA TAU MEDICAL LTD

Feed

News

Sentiment

Earnings

Fundamentals

Info

Historical Earnings

Latest DRTS News

DRTS
ALPHA TAU MEDICAL LTD